Differences in symptom scores and health outcomes in premenstrual syndrome

Journal of Women's Health

Volumn 16, Issue 8, 2007, Pages 1139-1144

  Borenstein, Jeff E ^a   Dean, Bonnie B ^b   Leifke, Eckhard ^c   Korner, Paul ^d   Yonkers, Kimberly A ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CERNER CORPORATION   (United States)

^c BAYER PHARMA AG   (Germany)

^d BAYER CORPORATION   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ALGORITHM; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SCORING SYSTEM; SHORT FORM 36; STATISTICAL SIGNIFICANCE;

ADULT; CALIFORNIA; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PREMENSTRUAL SYNDROME; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; WOMEN'S HEALTH;

EID: 35348842854     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.0230     Document Type: Article

References (8)

1. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. Available at www.fda.gov/cber/gdlns/clintrialend. htm#f10 Accessed January 25, 2006.
2. Szende A, Leidy NK, Revicki D. Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: A review of guidance documents and performed authorizations of medicinal products, 1995 to 2003. Value Health 2005;8:534.
3. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: A review of patient-reported outcomes and other efficacy endpoints in approved product labels. Controlled Clin Trials 2004;25:535.
4. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371.
5. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 2000:771.
6. Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003;48:515.
7. Sternfeld B, Swindle R, Chawla A, Long S, Kennedy S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002;99:1014.
8. Chawla A, Swindle R, Long S, Kennedy S, Sternfeld B. Premenstrual dysphoric disorder: Is there an economic burden of illness? Med Care 2002;40:1101.